How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?

14 Similarly in the National Cancer Research Institute AML17 study of standard-risk patients without NPM1 mutations, HSCT appeared to preferentially benefit those who remained MRD-positive by MFC after the second cycle of chemotherapy but not those who were MRD-negative, although the interaction between HSCT and MRD status did not reach statistical significance ( P =0.16), possibly because of the small number of patients in the cohort who underwent HSCT in first remission. 18 Although definitive evidence is lacking, collectively these studies provide some support for the use of MRD to guide post-remission therapies in patients with intermediate-risk AML.

also in 111,027 other papers